Immunotherapy with many ICIs targeting programmed cell death protein 1 (PD-1), PD-1 ligand (PD-L1), and CTL antigen-4 (CTLA-4) has significantly increased the clinical outcomes of melanoma patients13. This evidence concerns the gene PDCD1 and melanoma.